New drug combo offers hope for leukemia patients who Can't tolerate chemo
NCT ID NCT06985485
First seen Apr 04, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study tests a two-step immunotherapy approach for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older, too frail for standard chemo, or whose cancer has returned. Participants will receive two targeted drugs in sequence: blinatumomab and inotuzumab ozogamicin. The goal is to see if this drug-only regimen can improve survival and remission rates without the need for intensive chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.